Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.

Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.

Abstract: Methods of forming integrated circuit devices include forming a sacrificial layer on a handling substrate and forming a semiconductor active layer on the sacrificial layer. The semiconductor active layer and the sacrificial layer may be selectively etched in sequence to define an semiconductor-on-insulator (SOI) substrate, which includes a first portion of the semiconductor active layer. A multi-layer electrical interconnect network may be formed on the SOI substrate. This multi-layer electrical interconnect network may be encapsulated by an inorganic capping layer that contacts an upper surface of the first portion of the semiconductor active layer. The capping layer and the first portion of the semiconductor active layer may be selectively etched to thereby expose the sacrificial layer.

Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.

Abstract: Unique systems, methods, techniques and apparatuses of building power management are disclosed herein. One exemplary embodiment is a system comprising a load management controller and a power circuit interrupter. The load management controller is configured to repeatedly perform a first test wherein a time rate of change of temperature of building regions is determined, repeatedly perform a second test wherein a lighting controller is operated to rank a plurality of lighting loads according to ambient light of building regions associated with the plurality of lighting loads, assign the plurality of HVACR loads and lighting loads to a plurality of load shed groups, and reduce power consumption by the plurality of HVACR loads and the plurality of lighting loads in order of the ranked load shed groups effective to minimize occupant perceptibility of the power consumption reduction while implementing the operator specified priority criteria.

Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.

Abstract: Methods of forming integrated circuit devices include forming a sacrificial layer on a handling substrate and forming a semiconductor active layer on the sacrificial layer. The semiconductor active layer and the sacrificial layer may be selectively etched in sequence to define an semiconductor-on-insulator (SOI) substrate, which includes a first portion of the semiconductor active layer. A multi-layer electrical interconnect network may be formed on the SOI substrate. This multi-layer electrical interconnect network may be encapsulated by an inorganic capping layer that contacts an upper surface of the first portion of the semiconductor active layer. The capping layer and the first portion of the semiconductor active layer may be selectively etched to thereby expose the sacrificial layer.

Abstract: A bond adhesive composition comprising a polymer having a silicon-containing hydrolyzable terminal group and a hydrocarbon resin, where the composition is substantially devoid of phenolic resin.

Abstract: A process for forming a construction composite, the process comprising (i) providing a construction article having an adhesive coating layer of a curable pressure-sensitive adhesive; and (ii) subjecting the curable pressure-sensitive adhesive to UV radiation, where the amount of UV radiation imparted to the upper surface of the adhesive coating layer is from about 75 to about 125 millijoule/cm2, and where at least 60% of the radiation rays contributing to this power have an intensity of at least 200 milliWatts/cm2.

Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Abstract: A membrane composite comprising a polymeric membrane panel, an adhesive layer, and a release liner, where the adhesive layer is a pressure-sensitive adhesive that is at least partially cured, and includes at least two distinct regions with the at least two regions having distinct states of cure.

Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.

Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent ?v?6-mediated diseases such as fibrosis and cancer.

Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent ?v?6-mediated diseases such as acute tissue injury, fibrosis, and cancer.

Abstract: An optical power transfer device includes a transmitter circuit, including a laser light source that is configured to emit coherent light responsive to operation above a lasing threshold, and is configured to emit incoherent light responsive operation below the lasing threshold. A proximity sensor circuit is coupled to the transmitter circuit and is configured to output a detection signal therefrom responsive to authentication of an optical receiver including at least one photovoltaic cell having surface area of about 4 square millimeters or less within a proximity thereof. The transmitter circuit is configured to operate the laser light source below the lasing threshold to emit the incoherent light responsive to an absence of the detection signal from the proximity sensor circuit. Related devices and methods of operation are also discussed.

Abstract: A method for performing energy management for a building includes generating a stack of energy loads representative of a plurality of building energy loads. The energy loads are prioritized from highest priority energy loads to lowest priority energy loads. The prioritized energy loads are then compared to a building power threshold. The lowest priority energy loads are shed until a sum of remaining energy loads is equal to or less than the building power threshold. The remaining energy loads are serviced. The processes of prioritizing the energy loads, comparing the prioritized energy loads to a building power threshold, and shedding the lowest priority energy loads is repeated in response to changes in circumstances affecting the building.

Abstract: A microgrid is disclosed which includes a number of electrical loads and a number of potential grid forming sources. The potential grid forming sources can include an electrical grid, PhotoVoltaic (PV) system, energy storage system, and a generator, among potential others. The microgrid can operate in islanded mode. A controller can be used to control the powered state of the electrical loads and potential grid forming sources through use of a priority list of actions in which the controller determines whether adding or removing electrical loads will alleviate a power imbalance. In some forms the controller can tally the electrical loads by considering a potential power source (such as one of the potential grid forming sources placed in a mode to provide power to the microgrid) as a negative load. A validity check can be provided in the priority list to assist in determining whether an action can be taken.

Abstract: A method for controlling a temperature of a building using a building thermal model of the building in a model predictive control (MPC) system includes measuring the temperature and a rate of change of temperature for at least one zone that is included in the building thermal model so as to determine an error from a temperature and rate of change of temperature that is predicted by the MPC system. Possible causes of the error and a probability of each of the possible causes of error occurring are determined. An impact of each of the possible causes is evaluated so as to identify at least one of the possible causes which would reduce the error. The building thermal model is adapted based on the at least one identified possible cause and the temperature of the building is controlled using the adapted building thermal model in an MPC controller.